These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10147053)

  • 21. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
    Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
    Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monoclonal antibody therapy for gram-negative sepsis: principles, applications, and controversies.
    Mehra IV; Gottlieb JE; Nash DB
    Pharmacotherapy; 1993; 13(2):128-34. PubMed ID: 8469619
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Human monoclonal antibody against endotoxin.
    Zarowitz BJ
    DICP; 1991; 25(7-8):778-83. PubMed ID: 1949939
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Projected impact of monoclonal anti-endotoxin antibody therapy.
    Bates DW; Lee TH
    Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost effectiveness and budget impact of natalizumab in patients with relapsing multiple sclerosis.
    Chiao E; Meyer K
    Curr Med Res Opin; 2009 Jun; 25(6):1445-54. PubMed ID: 19422279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-drug resistance, inappropriate initial antibiotic therapy and mortality in Gram-negative severe sepsis and septic shock: a retrospective cohort study.
    Zilberberg MD; Shorr AF; Micek ST; Vazquez-Guillamet C; Kollef MH
    Crit Care; 2014 Nov; 18(6):596. PubMed ID: 25412897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antiendotoxin therapy in sepsis.
    Colletti RC; Dew RB; Goulart AE
    Crit Care Nurs Clin North Am; 1993 Jun; 5(2):345-54. PubMed ID: 8398040
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The search for a magic bullet to fight sepsis.
    Bone RC
    JAMA; 1993 May; 269(17):2266-7. PubMed ID: 8474207
    [No Abstract]   [Full Text] [Related]  

  • 29. Monoclonal anti-endotoxin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Baumgartner JD
    Eur J Clin Microbiol Infect Dis; 1990 Oct; 9(10):711-6. PubMed ID: 2261915
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of immunomodulator therapy in sepsis.
    Caplan ES
    Am J Surg; 1993 Feb; 165(2A Suppl):20S-25S. PubMed ID: 8438996
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [A cost-effectiveness analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
    Tebas P
    Med Clin (Barc); 1993 Dec; 101(19):757-8. PubMed ID: 8289526
    [No Abstract]   [Full Text] [Related]  

  • 32. Life-saving immunotherapy with cross-reactive monoclonal antibodies against endotoxin: a critical evaluation of experimental and clinical studies.
    Cornelissen JJ; Schellekens JF; Kraaijeveld CA; Verhoef J
    Neth J Med; 1991 Oct; 39(3-4):170-6. PubMed ID: 1791879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Centoxin: the full story of its withdrawal.
    Choyce MQ
    Br J Hosp Med; 1993 Apr 7-20; 49(7):517. PubMed ID: 8490694
    [No Abstract]   [Full Text] [Related]  

  • 34. Monoclonal antibodies for septic shock: in or out of the barn door?
    Nash DB; Johnson NE; Gottlieb JE; Vlasses PH
    QRB Qual Rev Bull; 1991 Oct; 17(10):310-3. PubMed ID: 1745528
    [No Abstract]   [Full Text] [Related]  

  • 35. [Preventive interruption of the administration of HA-1A monoclonal antibody against endotoxin].
    Torrabadella de Reynoso P; Trilla A; Salgado A; Ribas J
    Med Clin (Barc); 1993 Apr; 100(13):518. PubMed ID: 8479241
    [No Abstract]   [Full Text] [Related]  

  • 36. Comparison of the efficacy, safety, and therapeutic usage of HA-1A and E5 in the treatment of gram-negative sepsis.
    Quintiliani R; Cooper B; Maderazo E; Nightingale C
    Hosp Formul; 1992 Jan; 27(1):49-52, 54, 57-60. PubMed ID: 10116116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of polymyxin-B immobilized fiber column and conventional medical therapy in the management of abdominal septic shock in Italy.
    Berto P; Ronco C; Cruz D; Melotti RM; Antonelli M
    Blood Purif; 2011; 32(4):331-40. PubMed ID: 22086346
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-lipopolysaccharide and anti-tumor necrosis factor/cachectin antibodies for the treatment of gram-negative bacteremia and septic shock.
    Calandra T; Baumgartner JD; Glauser MP
    Prog Clin Biol Res; 1991; 367():141-59. PubMed ID: 1924424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monoclonal therapy for bacteremia and sepsis.
    Guglielmo J; Wiener-Kronish JP
    West J Med; 1992 Aug; 157(2):174. PubMed ID: 1441476
    [No Abstract]   [Full Text] [Related]  

  • 40. HA-1A. A human monoclonal antibody for the treatment of gram-negative sepsis.
    Smith CR; Straube RC; Ziegler EJ
    Infect Dis Clin North Am; 1992 Mar; 6(1):253-66. PubMed ID: 1578120
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.